Skip to main content

Table 5 Proportion of patients who received more than 80% of the target dose

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

 

Number of patients (%)

Time from randomization

DD/DI arm (N = 86)

HDI arm(N = 80)

Induction

56

(65)

52

(65)

3 months

35

(49)

42

(64)

5 months

25

(42)

33

(55)

7 months

20

(36)

23

(43)